Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentKathy S. Albain, Joyce O’Shaughnessy, Shona Nag et al.|Journal of Clinical Oncology|2008Cited by 422
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast CancerBruce E. Hillner, David G. Pfister, James N. Ingle et al.|Journal of Clinical Oncology|2000Cited by 383
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330